Statin Therapy & Pharmacology Flashcards

Beyond LDL-C lowering, statins exert pleiotropic cardiovascular benefits through which primary non-lipid mechanism?

Answer: Inhibition of isoprenoid synthesis reducing Rho GTPase activity and improving endothelial function

By blocking the mevalonate pathway, statins deplete isoprenoids (farnesyl pyrophosphate, geranylgeranyl pyrophosphate) needed for Rho GTPase prenylation, leading to anti-inflammatory and endothelium-protective effects independent of LDL lowering.

The LDL-C-lowering effect of statins follows which pharmacodynamic pattern regarding dose-response?

Answer: A logarithmic 'rule of 6' where each doubling of dose reduces LDL-C by an additional ~6%

The 'rule of 6' describes the statin dose-response: each doubling of the statin dose yields only an approximately 6% additional reduction in LDL-C beyond the initial 30–40% achieved at the starting dose.

Statins have been shown to reduce C-reactive protein (CRP) levels independent of LDL-C lowering. This anti-inflammatory effect was most prominently demonstrated in which landmark clinical trial?

Answer: JUPITER (Justification for the Use of Statins in Prevention)

The JUPITER trial enrolled patients with normal LDL-C but elevated hsCRP, demonstrating that rosuvastatin significantly reduced cardiovascular events, highlighting the anti-inflammatory pleiotropic benefit.

When comparing equivalent LDL-C-lowering doses, rosuvastatin achieves greater LDL-C reduction per milligram compared to atorvastatin. What approximate LDL-C reduction does rosuvastatin 10 mg achieve?

Answer: Approximately 37–45% reduction (moderate-intensity)

Rosuvastatin 10 mg achieves approximately 37–45% LDL-C reduction, classifying it as moderate-intensity therapy; only rosuvastatin 20–40 mg reaches high-intensity thresholds.

A patient requires statin therapy but has previously failed three different statins due to myalgia. Which alternative statin dosing strategy has randomized trial support (GAUSS-3 trial context) as bridging therapy before non-statin options?

Answer: Rosuvastatin 5–10 mg 2–3 times weekly (non-daily dosing)

Rosuvastatin 5–10 mg given 2–3 times per week (non-daily dosing) exploits its long half-life and is used as a strategy for statin-intolerant patients, with some evidence from trials and clinical practice guidelines.

Regarding statin effects on triglycerides, which statement is most accurate?

Answer: High-intensity statins can reduce triglycerides by approximately 10–30% in hypertriglyceridemic patients

High-intensity statins modestly reduce triglycerides (approximately 10–30%) in patients with elevated baseline levels, though they are not first-line agents for isolated severe hypertriglyceridemia.

Which mechanism explains why statins upregulate hepatic LDL receptor expression, their primary mechanism of LDL-C reduction?

Answer: HMGCR inhibition depletes intracellular cholesterol, activating SREBP-2 which transcriptionally upregulates LDL receptor gene expression

When statins block HMGCR and deplete hepatocyte cholesterol, SREBP-2 is proteolytically activated and translocates to the nucleus to upregulate LDL receptor transcription, increasing LDL clearance from plasma.